GlassScriptPhysician profile
Karen Baker
NPI 1699725242
$541.71
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $34.23 · 2021: $17.69 · 2022: $12.30 · 2023: $118 · 2024: $92.90 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $91.69 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $79.78 | 2022-2024 | |
| Hologic Sales and Service, LLC | $61.20 | 2023-2025 | Thinprep 2000 Processor, Omni Hysteroscope, Acessa Provu System |
| Abbvie INC. | $57.59 | 2019 | |
| Astellas Pharma US INC | $45.02 | 2023 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $34.23 | 2020 | |
| Therapeuticsmd, INC. | $31.00 | 2019 | |
| Sumitomo Pharma America, INC. | $23.56 | 2024 | Myfembree |
| Boston Scientific Corporation | $20.65 | 2024 | |
| Amag Pharmaceuticals, INC. | $19.67 | 2019 | |
| Agile Therapeutics, INC. | $17.69 | 2021 | |
| Lilly USA, LLC | $16.27 | 2025 | Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $15.92 | 2019 | |
| Octapharma USA, INC. | $14.60 | 2025 | Fibryga |
| Pfizer INC. | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.